Article Text

Download PDFPDF
Systematic review and meta-analysis
For patients with chronic asthma not controlled with inhaled corticosteroids alone, long-acting β-agonists are associated with fewer exacerbations than leukotriene receptor agonists
  1. Gene Colice
  1. Department of Medicine, George Washington University School of Medicine, Washington DC, USA
  1. Correspondence to : Dr Gene Colice, Critical Care and Respiratory Services, Washington Hospital Center, 110 Irving St NW, Washington, DC 20010, USA; Gene.Colice{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:


Outside of a clinical trial setting, most patients with asthma have poorly controlled asthma.1 ,2 Inadequate control of asthma in the community may reflect poor adherence to controller medications; however, the GOAL trial demonstrated that low-to-medium dose inhaled corticosteroids (ICS) were unsuccessful in achieving asthma control in a large proportion of patients with asthma, even with close supervision of care.3 Asthma management guidelines recommend an additional controller medication when asthma control is not achieved with ICS.4 Although the preferred second-choice controller medication is a long-acting inhaled β2-agonist (LABA), safety concerns regarding LABA use lead many clinicians to add a leukotriene receptor antagonist (LTRA) in its place. This review aimed to compare the efficacy and safety profiles of combinations …

View Full Text


  • Competing interests None.